Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Journal of Pharmacology

• Publication date

  2005-03-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.EJPHAR.2005.01.006PMID 15740725
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study.

  2002cited by this paper
• Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes.

  2002cited by this paper
• Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands.

  2001cited by this paper
• Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.

  2000cited by this paper
• Activational role of cannabinoids on movement.

  2000cited by this paper
• Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.

  2000cited by this paper
• Precipitated and spontaneous withdrawal in rats tolerant to anandamide

  2000cited by this paper
• Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Δ9-THC and anandamide1Published on the World Wide Web on 18 January 2000.1

  2000cited by this paper
• Time course for the induction and maintenance of tolerance to Δ9-tetrahydrocannabinol in mice

  2000cited by this paper
• Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9‐Tetrahydrocannabinol‐Tolerant Rats

  2000cited by this paper
• Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing.

  2000cited by this paper
• Effects of Δ9-tetrahydrocannabinol, (R)-methanandamide, SR 141716, and d-amphetamine before and during daily Δ9-tetrahydrocannabinol dosing

  2000cited by this paper
• Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice

  2000cited by this paper
• Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice.

  2000cited by this paper
• Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

  1999cited by this paper
• Synergistic interactions of endogenous opioids and cannabinoid systems.

  1999cited by this paper
• Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain.

  1999cited by this paper
• Chronic ▵9‐Tetrahydrocannabinol Treatment Produces a Time‐Dependent Loss of Cannabinoid Receptors and Cannabinoid Receptor‐Activated G Proteins in Rat Brain

  1999cited by this paper
• Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.

  1998cited by this paper
• Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.

  1998cited by this paper
• Time‐course of the cannabinoid receptor down‐regulation in the adult rat brain caused by repeated exposure to Δ9‐tetrahydrocannabinol

  1998cited by this paper
• Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.

  1997cited by this paper
• Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.

  1997cited by this paper
• Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.

  1997cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

  1996cited by this paper
• Anandamides: tolerance and cross-tolerance toΔ9-tetrahydrocannabinol

  1995cited by this paper
• Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.

  1995cited by this paper
• Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs.

  1995cited by this paper
• Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol.

  1995cited by this paper
• Pharmacological and behavioral evaluation of alkylated anandamide analogs.

  1995cited by this paper
• Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.

  1994cited by this paper
• The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.

  1994cited by this paper
• Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

  1993cited by this paper
• Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain.

  1993cited by this paper
• Cross‐tolerance between delta‐9‐tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212‐2 and anandamide

  1993cited by this paper
• Tolerance to the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol.

  1993cited by this paper
• Tolerance to the discriminative stimulus effects of Δ9-tetrahydrocannabinol

  1993cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992cited by this paper
• Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.

  1991cited by this paper
• Cannabis dependence and tolerance production.

  1990cited by this paper

• Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products

  2020cites this paper
• Approaches to Assess Biased Signaling at the CB1R Receptor.

  2017cites this paper
• Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497

  2016cites this paper
• Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice

  2016influential citation
• Discriminative Stimulus Properties of Endogenous Cannabinoid Degradative Enzyme Inhibitors

  2016cites this paper
• Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice.

  2014cites this paper
• Behavioral Assessment and HPLC/MS/MS Identification of the Synthetic Cannabinoid, CP47,497, in Mice

  2014cites this paper
• Operant nociception in nonhuman primates

  2014cites this paper
• The Directive 2010/63/EU on animal experimentation may skew the conclusions of pharmacological and behavioural studies

  2013cites this paper
• Behavioral Responses to Acute and Sub-chronic Administration of the Synthetic Cannabinoid JWH-018 in Adult Mice Prenatally Exposed to Corticosterone

  2013cites this paper
• Novel 3‐substituted rimonabant analogues lack Δ9‐tetrahydrocannabinol‐like abuse‐related behavioural effects in mice

  2013cites this paper
• Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice.

  2012cites this paper
• Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure.

  2012cites this paper
• Exposure to a high-fat diet decreases sensitivity to Δ9-tetrahydrocannabinol-induced motor effects in female rats.

  2011cites this paper
• Cannabinoid mediated diuresis in mice

  2011cites this paper
• Perceptual Drug Discriminative Aspects of the Endocannabinoid Signaling System in Animals And Man

  2011cites this paper
• Differential roles of the two major endocannabinoid hydrolyzing enzymes in cannabinoid receptor tolerance and somatic withdrawal

  2010cites this paper
• FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide Administration

  2010cites this paper
• To breed or not to breed? Empirical evaluation of drug effects in adolescent rats

  2009cites this paper
• Preclinical Pharmacological and Brain Bioassay Systems for CB1 Cannabinoid Receptors

  2009cites this paper
• Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog

  2009cites this paper
• Dose-Related Differences in the Regional Pattern of Cannabinoid Receptor Adaptation and in Vivo Tolerance Development to Δ9-Tetrahydrocannabinol

  2008cites this paper
• Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties.

  2008cites this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin

  2008cites this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

  2008cites this paper
• Cannabinoids: A novel treatment strategy for retinal neurodegenerative disorders

  2008cites this paper
• The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids : D 9-tetrahydrocannabinol , cannabidiol and D 9-tetrahydrocannabivarin

  2007cites this paper
• Pharmacological Effects of Acute and Repeated Administration of Δ9-Tetrahydrocannabinol in Adolescent and Adult Rats

  2007influential citation
• Marijuana: Pharmacology and Interaction with the Endocannabinoid System

  2007cites this paper
• Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor.

  2006cites this paper
• Targeting the endocannabinoid system in treating brain disorders

  2006cites this paper